Differential Expression of T-bet, a T-box Transcription Factor Required for Th1 T-Cell Development, in Peripheral T-Cell Lymphomas

American Journal of Clinical Pathology

Volumn 120, Issue 6, 2003, Pages 866-873

  Dorfman, David M ^a   Van Den Elzen, Peter ^a   Weng, Andrew P ^a   Shahsafaei, Aliakbar ^a   Glimcher, Laurie H ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Angioimmunoblastic; Lymphoepithelioid; Non Hodgkin lymphoma; Th1; Th2

Indexed keywords

CD134 ANTIGEN; CD30 ANTIGEN; CD69 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; LYMPHOID ENHANCER FACTOR 1; MARKER; T BET TRANSCRIPTION FACTOR; T BOX TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANAPLASTIC CARCINOMA; ANAPLASTIC LARGE CELL LYMPHOMA; ANGIOIMMUNOBLASTIC LYMPHOMA; ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; EPITHELIOID CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPHOEPITHELIOID LYMPHOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; TH1 CELL; TH2 CELL;

HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOID TISSUE; LYMPHOMA, T-CELL; LYMPHOPROLIFERATIVE DISORDERS; T-BOX DOMAIN PROTEINS; TH1 CELLS; TH2 CELLS; TRANSCRIPTION FACTORS;

EID: 0344827170     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/J3CTLTTJEVUY4YL0     Document Type: Article

References (26)

1. Mosman TR, Coffman RL. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145-173.
2. Seder RA, Paul WE. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol. 1994;12:635-673.
3. Szabo SJ, Kim ST, Costa GL, et al. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell. 2000;100:655-669.
4. Szabo SJ, Sullivan BM, Stemmann C, et al. Distinct effects of T-bet in Th1 lineage commitment and IFN-γ production in CD4 and CD8 T cells. Science. 2002;295:338-342.
5. Finotto S, Neurath MF, Glickman JN, et al. Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science. 2002;295:336-338.
6. Neurath MF, Weigman B, Finotto S, et al. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med. 2002;195:1129-1143.
7. Jones D, Fletcher CDM, Pulford K, et al. The T-cell activation markers CD30 and OX40/CD134 are expressed in nonoverlapping subsets of peripheral T-cell lymphoma. Blood. 1999;93:3487-3493.
8. Jones D, O'Hara C, Kraus MD, et al. Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. Blood. 2000;96:685-690.
9. Dorfman DM, Shahsafaei A. CD69 expression correlates with expression of other markers of Th1 T cell differentiation in peripheral T cell lymphomas. Hum Pathol. 2002;33:330-334.
10. Weng AD, Shahsafaei A, Dorfman DM. CXCR4/CD184 immunoreactivity in T-cell non-Hodgkin lymphomas with an overall Th1- Th2+ immunophenotype. Am J Clin Pathol. 2003;119:424-430.
11. Dorfman DM, Greisman HA, Shahsafaei A. Loss of expression of the WNT/beta-catenin signaling pathway transcription factors lymphoid enhancer protein-1 (LEF-1) and T cell factor-1 (TCF-1) in a subset of peripheral T cell lymphomas. Am J Pathol. 2003;162:1539-1544.
12. Caligaris-Cappio F, Bertero MT, Converso M, et al. Circulating levels of soluble CD30, a marker of cells producing Th2-like cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. Clin Exp Rheumatol. 1995;13:339-343.
13. D'Elios MM, Romagnani P, Scaletti C, et al. In vivo CD30 expression in human disease with predominant activation of Th2-like T cells. J Leukoc Biol. 1997;61:539-544.
14. Annunziato F, Manetti R, Cosmi L, et al. Opposite role for interleukin-4 and interferon-gamma on CD30 and lymphocyte activation gene-3 (LAG-3) expression by activated naive T cells. Eur J Immunol. 1997;27:2239-2244.
15. Jaffe ES, Harris NL, Stein H, et al, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:189-235. World Health Organization Classification of Tumours.
16. Bittner C, Feller AC, Renauld JC, et al. An animal model for anaplastic large cell lymphoma in the immunocompetent syngeneic C57BI/6 mouse. Lab Invest. 2000;80:1523-1531.
17. Merz H, Lange K, Gaiser T, et al. Characterization of a novel human anaplastic large cell lymphoma cell line tumorigenic in SCID mice. Leuk Lymphoma. 2002;43:165-172.
18. Grogan JL, Mohrs M, Harmon B, et al. Early transcription and silencing of cytokine genes underlie polarization of T helper cell subsets. Immunity. 2001;14:205-215.
19. Cousins DJ, Lee TH, Staynov DZ. Cytokine coexpression during human Th1/Th2 cell differentiation: direct evidence for coordinated expression of Th2 cytokines. J Immunol. 2002;169:2498-2506.
20. Melnyk A, Rodriguez A, Pugh WC, et al. Evaluation of the Revised European-American Lymphoma Classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood. 1997;89:4514-4520.
21. The Non-Hodgkin's Lymphoma Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood. 1997;89:3909-3918.
22. Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Blood. 1998;92:76-82.
23. Saez A-I, Artiga M-J, Sanchez-Beato M, et al. Analysis of octamer-binding transcription factors Oct2 and Oct1 and their coactivators BOB.1/OBF.1 in lymphomas. Mod Pathol. 2002;15:211-220.
24. Foss H-D, Reusch R, Demel G, et al. Frequent expression of the B-cell specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin. Blood. 1999;94:3108-3113.
25. Torlakovic E, Tierens A, Dang HD, et al. The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin's disease. Am J Pathol. 2001;159:1807-1814.
26. Ho I-C, Glimcher LH. Transcription: tantalizing times for T cells. Cell. 2002;109(suppl):S109-S120.